Artivion reported a 10% increase in revenue for the second quarter of 2024, driven by growth in On-X and stent grafts, as well as strong performance in Latin America and Asia Pacific. The company raised its full year revenue and adjusted EBITDA guidance.
Revenue of $98.0 million, a 10% increase year-over-year on a GAAP and constant currency basis.
Net loss of ($2.1) million, or ($0.05) per fully diluted share; non-GAAP net income of $2.9 million, or $0.07 per fully diluted share.
Adjusted EBITDA increased 35% to $18.6 million.
Raised FY24 revenue guidance to 10% to 12% year-over-year growth on a constant currency basis and adjusted EBITDA guidance to 28% to 34% year-over-year growth.
Artivion is raising its revenue guidance range and now expects constant currency revenue growth of between 10% to 12% for the full year 2024. Additionally, Artivion is raising its adjusted EBITDA guidance range and now expects growth of between 28% and 34% for the full year 2024.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance